白宫：最新药品关税不适用于已与美达成贸易协定国家！特朗普此前宣布对专利及品牌药品加征100%关税

Group 1 - The U.S. government announced that new tariffs on pharmaceuticals will not apply to countries with existing trade agreements, maintaining a 15% tariff cap for partners like the EU and Japan [1][2] - President Trump declared a 100% tariff on all brand-name and patented drugs starting October 1, complicating the recently established U.S.-EU pharmaceutical tariff agreement [2][3] - European pharmaceutical companies, including Roche, Novartis, and AstraZeneca, may benefit from exemptions if they have initiated drug production investments in the U.S., but most face new tariff barriers [2][3] Group 2 - The Belgian Pharmaceutical Association expressed concerns that the new tariffs violate the U.S.-EU agreement and could significantly impact multiple EU countries, creating uncertainty for investment decisions [3] - Economic analysts from Goldman Sachs and Morgan Stanley indicated that the tariffs could lead to increased prices for EU goods in the U.S., potentially passing the burden onto American consumers [4] - The U.S. economy is showing signs of slowing growth, with predictions of only 1.25% growth in 2026, significantly lower than the expected 2.8% in 2024, partly due to the impact of tariff policies [4]